Renal Cell Carcinoma Rcc clinical trials

Explore recruiting renal cell carcinoma rcc clinical trials.

Recruiting renal cell carcinoma rcc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Renal Cell Carcinoma Rcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies

Italy, Bulgaria, Poland, Romania, France, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Hungary, Finland, Sweden, Netherlands, Ireland, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment

Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma

Sweden, Poland, France, Germany, Italy, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

AN OPEN-LABEL PHASE 2 STUDY TO EVALUATE PT2977 FOR THE TREATMENT OF VONHIPPEL-LINDAU DISEASE-ASSOCIATED RENAL CELL CARCINOMA

Denmark, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Germany, Ireland, Hungary, Austria, Spain, Netherlands +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Renal Cell Carcinoma Rcc trials by city

Renal Cell Carcinoma Rcc in Toronto Renal Cell Carcinoma Rcc in Vancouver Renal Cell Carcinoma Rcc in Montreal Renal Cell Carcinoma Rcc in Calgary Renal Cell Carcinoma Rcc in Edmonton Renal Cell Carcinoma Rcc in Ottawa Renal Cell Carcinoma Rcc in Winnipeg Renal Cell Carcinoma Rcc in Quebec City Renal Cell Carcinoma Rcc in Hamilton Renal Cell Carcinoma Rcc in Kitchener Renal Cell Carcinoma Rcc in London Renal Cell Carcinoma Rcc in Halifax Renal Cell Carcinoma Rcc in New York Renal Cell Carcinoma Rcc in Los Angeles Renal Cell Carcinoma Rcc in Chicago Renal Cell Carcinoma Rcc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease